Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million). The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures. In… Read More
CDMO Cambrex has begun construction on a new R&D facility in Milan, Italy, a $30 million investment will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants. The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future… Read More
Sentynl Therapeutics and Mereo BioPharma have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Alvelestat is a neutrophil elastase inhibitor being readied for Phase III and, if approved, would be the… Read More
Cure Sanfilippo Foundation and the National MPS Society have agreed a combined $5.5 million strategic investment in Spruce Biosciences, which will go towards the Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for Sanfilippo Syndrome Type B (or MPS IIIB) Expanded Access Program (EAP). Samir Gharib, President and Chief… Read More
CN Bio, a provider of organ-on-a-chip (OOC) systems, has been awarded £180k ($243k) grant funding from Innovate UK. Delivered in partnership with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), the funding aims to support new approach methodologies (NAMs) for… Read More
Boulevard Bio has emerged from stealth with $65 million from founding investor Deerfield Management and early Phase I healthy volunteer data for lead candidate BLVD101. Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), Boulevard’s approach is grounded… Read More
MindMaze Therapeutics has announced the completion of its organisational simplification initiative, and the implementation of its CHF 8 ($9.8) million strategic equity financing with Neuro.io Group. The company’s organisational simplification initiative included the selling of substantially all remaining non-neurology legacy operations acquired through its business combination with… Read More
AstronauTx has secured the exclusive worldwide rights to research, develop, manufacture and commercialise therapeutic candidates arising from its collaboration with biopharma company Saniona. Saniona and AstronauTx entered into a research collaboration and option agreement in 2023 to discover new treatments for neurological conditions by modulating a novel,… Read More
Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey will use Evotec’s data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across… Read More
Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company. The companies expect the transaction to generate significant value for stockholders of both companies, realising… Read More
Antiviral therapeutics company Cocrystal Pharma has announced a $5 million investment from OPKO Health, a longtime investor in the company. The investment will support Cocrystal as it advances its lead norovirus programme towards Phase Ib topline data later this year. Under the terms of the agreement,… Read More
Processa Pharmaceuticals has acquired Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton’s tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. The product is initially focused on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS). Concurrent… Read More
Pharmaceutical company GSK has announced a strategic collaboration with the biotech Relation to improve the understanding of disease biology and support the discovery of new therapeutic targets. Specifically, the partnership will focus on generating large-scale human cellular perturbation data and deploying them into models, such as Relation’s… Read More
Norstella has announced the launch of the Pipeline-to-Patient Productivity Index (P3i), a new annual benchmark measuring R&D productivity, market access, and commercial return across the top 25 global biopharma companies. The P3i is the first benchmark to follow drug performance across the entire development and commercialisation lifecycle. Read More
GSK has announced plans to establish a major new global R&D centre in Cambridge, UK, as part of the company’s plan to accelerate its R&D pipeline. The new 300,000 square foot site, on the Cambridge Biomedical Campus in the heart of the UK’s life sciences “Golden Triangle,”… Read More
Axiom Biosciences has announced plans to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong (HKEX). The company says it believes the proposed listing would position it as the first US biotechnology company to pursue a primary listing in Hong… Read More
